ANRO Alto Neuroscience, Inc.
Legal ·
A federal court in California dismissed the securities class action over Alto Neuroscience's ALTO-100 disclosures on August 7, 2026, and gave the plaintiffs leave to file a third amended complaint. A related derivative action has been stayed.
Alto may owe up to $71,500,000 in milestone payments, payable in cash or restricted stock, and says its cash is still expected to fund operations into 2028.
Alto Neuroscience filed a $300,000,000 shelf on February 3, 2025 and signed a $75,000,000 at-the-market sales agreement with Leerink Partners LLC, but no sale can start until the SEC declares the shelf effective, and its year-end cash figure is still preliminary.
Alto Neuroscience's January 13, 2025 amendment lifts the maximum term loans from $35.0 million to $75.0 million and moves maturity to January 1, 2029. Only $20.0 million was funded at signing, and about $10 million of that went to refinance the old loan and pay fees.
Alto Neuroscience is a clinical-stage biopharmaceutical company that aims to redefine psychiatry through its Precision Psychiatry Platform, which discovers brain-based biomarkers to identify which patients are more likely to respond to its product candidates. The company has seven clinical-stage assets addressing major depressive disorder, bipolar depression, treatment resistant depression, schizophrenia and Parkinson's disease. Its most advanced program is ALTO-207, a fixed-dose combination of pramipexole and ondansetron that the company acquired in May 2025 from Chase Therapeutics Corporation. ALTO-207 is being developed for treatment resistant depression, and the company plans a Phase 2b trial. The platform collects data from neurocognitive assessments, electroencephalography, wearable devices and genetic samples, and applies machine learning. The company reports biomarker collection across more than 70 unique clinical sites and from over 2,000 participants.
| Product or program | What it is | Stage |
|---|---|---|
| ALTO-207 | Fixed-dose pramipexole and ondansetron combination for treatment resistant depression | Phase 2b planned; Phase 3 expected to start by early 2027 |
| Precision Psychiatry Platform | Brain biomarker discovery using EEG, neurocognitive assessments and wearable devices | biomarker collection across more than 70 unique clinical sites |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $45.6 million | $47.0 million |
| Net income (loss) | -$63.2 million | -$61.4 million |
| Cash from operations | -$51.8 million | -$47.4 million |
| Cash and equivalents | $176.5 million | $168.2 million |
Opinion Mixed view
Alto reports $243.7 million, plus $94.6 million net from a July offering. Our arithmetic gives 43 to 59 months. But ALTO-100 and ALTO-101 both missed in Phase 2, and quarterly spending is up sharply.
Our latest story on this, dated Aug 12, 2026: "Alto Neuroscience IPO securities class action dismissed with leave to amend". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 12, 2026: "Alto Neuroscience IPO securities class action dismissed with leave to amend". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 3, 2025: "Alto Neuroscience files $300,000,000 shelf with $75,000,000 at-the-market program". The story links the filing or release it is based on. Read the story.
Alto Neuroscience, Inc. trades under the ticker ANRO on NYSE.
Alto Neuroscience, Inc. is listed on NYSE.
The SEC Central Index Key (CIK) for Alto Neuroscience, Inc. is 1999480. Its filings are on SEC EDGAR.
39,242,104 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Alto Neuroscience, Inc. under United States.
Our directory classifies Alto Neuroscience, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Alto Neuroscience, Inc. is US02157Q1094.
aibio.space lists Alto Neuroscience, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Alto Neuroscience is a clinical-stage biopharmaceutical company that aims to redefine psychiatry through its Precision Psychiatry Platform, which discovers brain-based biomarkers to identify which patients are more likely to respond to its product candidates. The company has seven clinical-stage assets addressing major depressive disorder, bipolar depression, treatment resistant depression, schizophrenia and Parkinson's disease.
ALTO-207: Fixed-dose pramipexole and ondansetron combination for treatment resistant depression Stage: Phase 2b planned; Phase 3 expected to start by early 2027.
Precision Psychiatry Platform: Brain biomarker discovery using EEG, neurocognitive assessments and wearable devices Stage: biomarker collection across more than 70 unique clinical sites.
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a financing. SEC Form 8-K (Items 1.01,1.02,3.02,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a financing. SEC Form S-3. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio